Sameh S Ali1,2, El-Refaie Kenawy3, Fatma I Sonbol4, Jianzhong Sun5, Marwa Al-Etewy3, Asmaa Ali6, Liu Huizi7, Nessma A El-Zawawy8. 1. Biofuels Institute, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, China. samh_samir@science.tanta.edu.eg. 2. Botany Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt. samh_samir@science.tanta.edu.eg. 3. Polymer Research Group, Department of Chemistry, Faculty of Science, Tanta University, Tanta, 31527, Egypt. 4. Department of Microbiology, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt. 5. Biofuels Institute, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, China. jzsun1002@ujs.edu.cn. 6. Ministry of Health and Population, Chest Directorate, Abbassia Chest Hospital, Cairo, Egypt. 7. Biofuels Institute, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, China. 8. Botany Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Abstract
PURPOSE: Chitosan and its derivatives possess several unique properties relevant in the field of pharmaceutics and medicinal chemistry. This study aimed to evaluate the pharmaceutical performance of an innovative chitosan derivative, methyl acrylate chitosan bearing p-nitrobenzaldehyde (MA*CS*pNBA) Schiff base. METHODS: The antibacterial activity of MA*CS*pNBA was tested against multi-drug resistant (MDR) Gram-negative and Gram-positive bacteria using agar-well diffusion method. Anti-biofilm formation was analyzed using a microtitre plate. Antioxidant assays were performed to assess the scavenging activity of MA*CS*pNBA using DPPH, hydrogen peroxide, superoxide together with its reducing power activity. Anti-inflammatory activity was evaluated by albumin denaturation, membrane stabilization, and proteinase inhibition methods. MA*CS*pNBA was tested for its hemolytic efficiency on human erythrocytes. Cytotoxicity of MA*CS*pNBA was evaluated by MTT assay. RESULTS: MA*CS*pNBA showed a significant performance as an antibacterial candidate against MDR bacteria, anti-biofilm, antioxidant and anti-inflammatory biomaterial, evidencing hemocompatibility and no cytotoxicity. It exhibited a significant negative correlation with biofilm formation by the MDR-PA-09 strain. Biological activities were found to be significantly concentration-dependent. CONCLUSIONS: the newly chitosan derivative MA*CS*pNBA showed to be promising for pharmaceutical applications, expanding the treatment ways toward skin burn infections since it allied excellent antibacterial, anti-biofilm, antioxidant, anti-inflammatory, hemocompatibility and absence of cytotoxic activities.
PURPOSE: Chitosan and its derivatives possess several unique properties relevant in the field of pharmaceutics and medicinal chemistry. This study aimed to evaluate the pharmaceutical performance of an innovative chitosan derivative, methyl acrylate chitosan bearing p-nitrobenzaldehyde (MA*CS*pNBA) Schiff base. METHODS: The antibacterial activity of MA*CS*pNBA was tested against multi-drug resistant (MDR) Gram-negative and Gram-positive bacteria using agar-well diffusion method. Anti-biofilm formation was analyzed using a microtitre plate. Antioxidant assays were performed to assess the scavenging activity of MA*CS*pNBA using DPPH, hydrogen peroxide, superoxide together with its reducing power activity. Anti-inflammatory activity was evaluated by albumin denaturation, membrane stabilization, and proteinase inhibition methods. MA*CS*pNBA was tested for its hemolytic efficiency on human erythrocytes. Cytotoxicity of MA*CS*pNBA was evaluated by MTT assay. RESULTS: MA*CS*pNBA showed a significant performance as an antibacterial candidate against MDR bacteria, anti-biofilm, antioxidant and anti-inflammatory biomaterial, evidencing hemocompatibility and no cytotoxicity. It exhibited a significant negative correlation with biofilm formation by the MDR-PA-09 strain. Biological activities were found to be significantly concentration-dependent. CONCLUSIONS: the newly chitosan derivative MA*CS*pNBA showed to be promising for pharmaceutical applications, expanding the treatment ways toward skin burn infections since it allied excellent antibacterial, anti-biofilm, antioxidant, anti-inflammatory, hemocompatibility and absence of cytotoxic activities.
Authors: Estefania Grotz; Nancy Tateosian; Nicolas Amiano; Maximiliano Cagel; Ezequiel Bernabeu; Diego A Chiappetta; Marcela A Moretton Journal: Pharm Res Date: 2018-09-20 Impact factor: 4.200
Authors: Luca Casettari; Enzo Castagnino; Snjezana Stolnik; Andrew Lewis; Steven M Howdle; Lisbeth Illum Journal: Pharm Res Date: 2011-03-11 Impact factor: 4.200
Authors: Wagih A El-Shouny; Sameh S Ali; Hegazy M Hegazy; Manar K Abd Elnabi; Asmaa Ali; Jianzhong Sun Journal: J Tradit Complement Med Date: 2019-05-15
Authors: Mahmoud H Teaima; Mohamed K Elasaly; Samia A Omar; Mohamed A El-Nabarawi; Kamel R Shoueir Journal: Saudi Pharm J Date: 2020-06-18 Impact factor: 4.330